Stocks and Investing Stocks and Investing
Tue, October 13, 2020

Matthew Harrison Maintained (VRTX) at Hold with Decreased Target to $281 on, Oct 13th, 2020


Published on 2024-10-27 14:20:21 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Decreased Target from $300 to $281 on, Oct 13th, 2020.

Matthew has made no other calls on VRTX in the last 4 months.



There are 8 other peers that have a rating on VRTX. Out of the 8 peers that are also analyzing VRTX, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $276 on, Sunday, October 4th, 2020
  • Geoffrey Porges of "SVB Leerink" Maintained at Hold with Increased Target to $283 on, Monday, August 24th, 2020


These are the ratings of the 6 analyists that currently disagree with Matthew


  • Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $309 on, Friday, July 31st, 2020
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $315 on, Friday, July 31st, 2020
  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $305 on, Friday, July 31st, 2020
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $315 on, Friday, July 31st, 2020
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $328 on, Monday, July 20th, 2020
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $330 on, Thursday, July 2nd, 2020
Contributing Sources